ClinicalTrials.gg
RecruitingNCT07038967Updated Jul 1, 2025

Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification

An observational study in Non-Center, Diabetic Macular Edema and Phacoemulsification, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Ain Shams University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Macular Edema with a site in Egypt — 5 open to participants now, 5 under way, none of them phase 3. Macular Edema · Egypt.

Started
2025
with 2 others
Observational
5 of 22
2 open now
Registered
19th of 22
by date
Lead sponsor
2 of 22
Ain Shams University

Among the 22 studies in Macular Edema with a site in Egypt, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 19th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

5 of the 22 studies in Macular Edema with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Macular Edema with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate the progression of non-center-involving diabetic macular edema in the early postoperative period following phacoemulsification.

Read the detailed description

Diabetic patients have been reported to have a higher prevalence of cataract and develop it at an earlier age compared with nondiabetic individuals.

According to recent population-based studies, diabetic macular edema (DME) is the most common cause of vision loss, with the incidence of non-center-involving DME (NCIDME) being higher than that of center-involving DME (CIDME). The prevalence of NCIDME in an urban south Indian population is 10.8%.

03

Conditions studied

  • Non-Center
  • Diabetic Macular Edema
  • Phacoemulsification

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This prospective study will be conducted on 50 diabetic patients aged ≥18 years, both sexes, with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Both sexes.
  • Patients with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME).

Exclusion criteria

Exclusion Criteria:

  • Traumatic cataract.
  • Severe Non-Proliferative/ Proliferative Diabetic Retinopathy.
  • Marked Asymmetry of retinopathy between both eyes.
  • Mature senile cataract or severe lens opacity.
  • Potentiality to have Phacotrabeculectomy surgery.
  • Complications during or after the surgery.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Study group

    Patients with Grade I - Grade II nuclear cataract and non-center-involving diabetic macular edema (NCIDME)

    Other: Coloured photography · Other: Fluorescein angiography · Other: Optical coherence tomography

Interventions

  • OtherColoured photography

    Coloured photography will be performed preoperatively and at 3 and 6 months postoperatively.

  • OtherFluorescein angiography

    Fluorescein angiography will be performed preoperatively and at 3 and 6 months postoperatively. The following features will be recorded on each angiography:

  • OtherOptical coherence tomography

    Optical coherence tomography (OCT) scanning will be performed using the optical coherence tomography scanner OCT (OPTOVUE OCT). OCT will be performed preoperatively and at 3 and 6 months postoperatively.

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    Best Corrected Visual Acuity (BCVA) will be recorded.

    Time frame: 6 months post-procedure

Secondary outcomes

  1. Intra ocular pressure

    Intra ocular pressure (IOP) will be recorded.

    Time frame: 6 months post-procedure

  2. Central macular thickness (CMT)

    Central macular thickness (CMT) will be recorded.

    Time frame: 6 months post-procedure

  3. Frequency distribution of Fluorescein leakage

    Frequency distribution of Fluorescein leakage will be recorded.

    Time frame: 6 months post-procedure

07

Study locations

1 of 1 sites recruiting
  • Ain Shams University
    Cairo, 11591, Egypt
    Recruiting
    • Hatem F Abd Elfatah, MD · Contacttito78@yahoo.com · 00201001859927
    • Samah M Fawzy, MD · Principal investigator
    • Tarek M Saad, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 5 months after the start.

Of 44 observational studies under Macular Edema, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 52. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2025
First posted
Jun 26, 2025
StartActual
Jun 29, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07038967
Responsible party
Hatem Fawzy Abd Elfatah Abo saif (Lecturer of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt., Ain Shams University) — Principal investigator
First posted
Jun 26, 2025
Start date
Jun 29, 2025
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Jul 1, 2025

Study contacts

Hatem F Abd Elfatah, MD
Contact
tito78@yahoo.com
00201001859927

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion